



ASX ANNOUNCEMENT

23 April 2008

## Further Positive VitroGro® Preclinical Results & Clinical Trial Update



Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has achieved a further confirmation of the power of VitroGro® to produce accelerated, scarless wound healing.

The most recent trial conducted in February and March 2008 has demonstrated that when VitroGro® is used to treat acute incisional wounds, such as donor site or surgical wounds:

1. healing is faster with VitroGro, with complete wound closure (re-epithelialisation) at day 8, compared to day 10 for all other groups; and
2. it appears by both visual inspection of the wound as well as microscopic examination that VitroGro® reduces inflammation and swelling. This suggests VitroGro may improve patient comfort and reduce scarring.

It is also evident that the healing of acute wounds stimulated by VitroGro® results in an excellent cosmetic result, with substantial restoration of normal skin pigmentation, as can be seen in the example study photographs (please see next page).

Cont/ 2



**A = Control ie. inert liquid      B = VitroGro®**

Professor Zee Upton said “This is a further validation of the power of VitroGro® to improve wound healing and to produce an excellent cosmetic result.”

The CEO of Tissue Therapies, Dr Steven Mercer said “I am particularly pleased that we now have evidence of the ability of VitroGro® to not only heal acute wounds, but to rapidly restore normal skin at the injury site. This is in addition to the data we already have demonstrating the ability of VitroGro® to produce accelerated, scarless healing of burns and the restoration of normal healing responses in laboratory studies of human skin cells from the margins of diabetic ulcers.”

Prior preclinical studies have shown to high levels of statistical significance that when used to treat burns, VitroGro® accelerates healing, reduces contraction and reduces the formation of granulation tissue that produces scarring.

Dr Mercer also provided an update on the clinical trial of VitroGro® in Toronto for the treatment of diabetic, venous and pressure ulcers; “In completing the final step necessary for commencement of the clinical trial of VitroGro® Tissue Therapies has answered a number of minor queries from Health Canada. We are confident that the human trial of VitroGro® for the treatment of skin ulcers will commence imminently.”

Cont/ 3

Dr Mercer reconfirmed that the Health Canada classification of VitroGro® for wound healing is a Class IV Medical Device, not as a pharmaceutical or a lower Class Device. This Class IV Device classification has the commercial benefits of avoiding the costs and time of a pharmaceutical clinical trial and regulatory approval, while allowing Tissue Therapies to make specific claims about the ability of VitroGro® to accelerate wound healing. This will also allow sales and distribution by traditional devices/wound care companies instead of limiting sales of VitroGro® products only through pharmaceutical companies.

## **ENDS**

Further information: Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: 07 3839 9938  
  
Email: [s.mercer@tissuetherapies.com](mailto:s.mercer@tissuetherapies.com)

## **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

**More information:** [www.tissuetherapies.com](http://www.tissuetherapies.com)